Skip to content
Fear and GreedStocks35Crypto24
Start for free

PACS Group stock

PACSNYSE

PACS Group, Inc., HealthcareISIN US69380Q1076

$50.06▲ $0.96 (+2.0%)Closing price of 11 Nov 2026

67Score 67 out of 100, Neutral

Turn on early warning

Price and trend

89 / 100

Price history

+307% in one year

The chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Above the 200-day line: the price is 24% above it.

Trend change

Since October 2025 the 50-day line has been above the 200-day line; the trend has turned up.

Momentum

Normal: the price is neither overheated nor sold off (RSI 58).

Distance to the high

The price is at its 52-week high. Largest decline in 3 years: 82% (November 2024 to September 2025).

Chart figures for advanced users
SMA 50$45.02
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$40.22
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)58
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDabove the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$10.58
The lowest closing price of the last twelve months.
Resistance$50.26
The highest closing price of the last twelve months.
What would $1,000 in PACS Group have become?Return triangle for PACS Group
Market cap
$7.95B
Div. yield
no dividend
29.6
Fair value
$64.64

Snapshot

Computed from the data by fixed rules, no AI

  • PACS Group, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $7.95B, is number 13 of 56 companies in its industry on MEQIRI.
  • In fiscal 2025 it reported revenue of $5.29B (up 29.3% year on year) and earnings of $191.54M (up 243.5%).
  • For fiscal 2026, analysts expect on average revenue of $5.91B (up 11.7%) and adjusted earnings per share of $2.41 (up 39.1%).
Show more
  • MEQIRI Score 67 out of 100 (Neutral): rank 187 of 714 in Healthcare, median 53.
  • The P/E is 29.6 (Medical (Care Facilities) median 19.4, own median of recent years 32.9).
  • Our model puts fair value at $64.64, with the price 23% below it.

In plain words

The numbers on this page in plain words, written by an AI

Strengths

  • Growing faster than its industryRevenue up 45.9% a year since 2021, Medical (Care Facilities) median 9.2%.Growth 88
  • Earnings per share growingUp 40% a year since 2021.Growth 88
  • Earnings turn into cashFree cash flow 161% of earnings over the last 12 months.Fundamentals 79

Weaknesses

  • High debtDebt 2.82 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 33
  • Volatile share priceVolatility 93% a year over the last 12 months.Stability 33
67/ 100
MEQIRI Score
Neutral

Its standout strengths are momentum and technical analysis, while capital allocation and stability hold the score back.

Daily figure as of 12 Nov 2026

How the score is calculated

Score overview

Fundamentals are strong, with stable profits and strong cash generation.

Profit consistency100% of years
Cash conversion (free cash flow to earnings, 12 months)161%
ROIC (12 months)7.0%
Positive free cash flow80% of years
How this category is measured

Score history

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Crash risk medium

How well MEQIRI warns

In the middle among smaller stocks.

From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.

What drives the risk

  • high growth grade (crashed more often in the backtest)

What lowers it

  • price near its 52-week high
  • solid fundamentals
  • stable momentum

Valuation

Valuation signal

Modestly undervalued
Price
$50.06
Fair value
$64.64
Gap to fair value
−23%

In our model the price counts as cheap below $43.10 and expensive above $129.29 (uncertainty very high, based on the price swings of the past year).

The two parts of the fair value come to $96.50 (cash-flow model) and $32.79 (industry comparison), and the gap between them shows how uncertain the estimate is.

Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $55.66, at 7.8% it would be $78.20.

Valuation metrics

2.67
23.2
Fair value (model)
$64.64
Earnings part $32.79 (earnings per share $1.69 × 19.4)

Half from the cash-flow model, half from earnings times the industry P/E (19.4).

Calculate with your own assumptions

Company performance

This shows several years of history with an automatic assessment.

Revenue

5 years

In the twelve months to 30 Sep 2026, revenue rose 11% on the twelve months before. Revenue has grown strongly since 2021, at around 46% per year.

Margins

5 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2025: gross 22%, operating 6%, net 4%.

Debt & balance sheet

latest quarter
2.82
10.9x
0.8
Cash & equivalents
$115.28M

Meaningfully leveraged, but the interest bill is comfortably covered.

Earnings

Next earnings
25 Feb 2027in 105 days
Last reported
3 Nov 2026EPS reported $0.63 (expected $0.58)above expectations

Analyst estimates

Earnings estimates have barely changed since 15 Oct 2026.

Fiscal 20264 analysts
Earnings per share
$2.41−1.1%
Revenue
$5.91B+1.0%
Fiscal 20274 analysts
Earnings per share
$2.71+0.3%
Revenue
$6.69B+2.2%

MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.

Company outlook raised

Share price after the results: +4.2%

2026 revenue guidance raised to $5.75 to $5.85 billion (up $100 million) and adjusted EBITDA to $640 to $660 million (up $35 million).

Supporting passage from the call, verbatim
“As noted in our earnings release, we're increasing our full year revenue guidance to a range of $5.75 billion to $5.85 billion, which is up $100 million on both ends of the range from our previous range of $5.65 billion to $5.75 billion.”

The outlook is not part of the score and not a recommendation to buy or sell.

From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.

Insiders

Open-market purchases and sales by executives, board members and major holders

All insider purchases

No open-market purchases in the last 6 months. 6 insiders sold, $115.84M in total.

Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.

  • Murray Jason HulseSale

    5 Nov 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    19,235
    Price
    $50.64
    Value
    $974,027
  • Lewis Michelle ReneeSale

    4 Nov 2026, Chief Accounting Officer

    Shares
    3,172
    Price
    $50.06
    Value
    $158,776
  • Murray Jason HulseSale

    4 Nov 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    167,434
    Price
    $50.24
    Value
    $8.41M
Show 61 more
  • Hancock MarkSale

    4 Nov 2026, Board

    Shares
    186,696
    Price
    $50.45
    Value
    $9.42M
  • Murray Jason HulseSale

    3 Nov 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    26,504
    Price
    $46.50
    Value
    $1.23M
  • Murray Jason HulseSale

    2 Nov 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    31,358
    Price
    $46.02
    Value
    $1.44M
  • Lewis Michelle ReneeSale

    29 Oct 2026, Chief Accounting Officer

    Shares
    2,364
    Price
    $50.04
    Value
    $118,283
  • Murray Jason HulseSale

    29 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    1,904
    Price
    $50.05
    Value
    $95,289
  • Hancock MarkSale

    29 Oct 2026, Board

    Shares
    4,280
    Price
    $50.02
    Value
    $214,101
  • Lewis Michelle ReneeSale

    28 Oct 2026, Chief Accounting Officer

    Shares
    9,464
    Price
    $50.12
    Value
    $474,365
  • Murray Jason HulseSale

    28 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    6,899
    Price
    $50.10
    Value
    $345,624
  • Hancock MarkSale

    28 Oct 2026, Board

    Shares
    9,024
    Price
    $50.10
    Value
    $452,120
  • Murray Jason HulseSale

    23 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    68,917
    Price
    $48.60
    Value
    $3.35M
  • Murray Jason HulseSale

    22 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    13,696
    Price
    $47.55
    Value
    $651,211
  • Murray Jason HulseSale

    21 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    6,610
    Price
    $47.62
    Value
    $314,755
  • Murray Jason HulseSale

    20 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    37,477
    Price
    $47.65
    Value
    $1.79M
  • Murray Jason HulseSale

    19 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    1,620
    Price
    $47.57
    Value
    $77,060
  • Murray Jason HulseSale

    16 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    8,462
    Price
    $47.61
    Value
    $402,876
  • Murray Jason HulseSale

    15 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    110,035
    Price
    $47.27
    Value
    $5.2M
  • Jergensen JoshuaSale

    14 Oct 2026, President & COO

    Shares
    40,000
    Price
    $44.50
    Value
    $1.78M
  • Murray Jason HulseSale

    14 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    232
    Price
    $45.00
    Value
    $10,440
  • Murray Jason HulseSale

    7 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    717
    Price
    $42.48
    Value
    $30,458
  • Murray Jason HulseSale

    6 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    35,975
    Price
    $43.09
    Value
    $1.55M
  • Murray Jason HulseSale

    5 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    24,224
    Price
    $42.66
    Value
    $1.03M
  • Murray Jason HulseSale

    2 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    26,052
    Price
    $42.51
    Value
    $1.11M
  • Murray Jason HulseSale

    1 Oct 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    33,032
    Price
    $41.13
    Value
    $1.36M
  • Jergensen JoshuaSale

    16 Sept 2026, President & COO

    Shares
    40,000
    Price
    $43.13
    Value
    $1.73M
  • Hancock MarkSale

    15 Sept 2026, Board

    Shares
    155,682
    Price
    $42.47
    Value
    $6.61M
  • Hancock MarkSale

    14 Sept 2026, Board

    Shares
    144,318
    Price
    $44.57
    Value
    $6.43M
  • Murray Jason HulseSale

    14 Sept 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    317
    Price
    $45.03
    Value
    $14,275
  • Murray Jason HulseSale

    11 Sept 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    10,529
    Price
    $45.23
    Value
    $476,190
  • Murray Jason HulseSale

    10 Sept 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    8,771
    Price
    $45.16
    Value
    $396,105
  • Murray Jason HulseSale

    9 Sept 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    4,758
    Price
    $43.33
    Value
    $206,147
  • Murray Jason HulseSale

    8 Sept 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    24,057
    Price
    $43.49
    Value
    $1.05M
  • Murray Jason HulseSale

    4 Sept 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    23,072
    Price
    $42.69
    Value
    $984,899
  • Murray Jason HulseSale

    3 Sept 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    20,173
    Price
    $42.56
    Value
    $858,483
  • Murray Jason HulseSale

    2 Sept 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    23,783
    Price
    $42.94
    Value
    $1.02M
  • Murray Jason HulseSale

    1 Sept 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    24,157
    Price
    $42.39
    Value
    $1.02M
  • Murray Jason HulseSale

    21 Aug 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    59,244
    Price
    $43.90
    Value
    $2.6M
  • Murray Jason HulseSale

    20 Aug 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    91,306
    Price
    $43.92
    Value
    $4.01M
  • Murray Jason HulseSale

    19 Aug 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    84,717
    Price
    $44.26
    Value
    $3.75M
  • Murray Jason HulseSale

    18 Aug 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    66,797
    Price
    $44.18
    Value
    $2.95M
  • Murray Jason HulseSale

    17 Aug 2026, 10 percent owner, officer: Co-Founder, CEO & Chairman

    Shares
    84,602
    Price
    $44.16
    Value
    $3.74M
  • Conway Patrick HughSale

    14 Aug 2026, Board

    Shares
    3,497
    Price
    $44.41
    Value
    $155,302
  • Jergensen JoshuaSale

    12 Aug 2026, President & COO

    Shares
    40,000
    Price
    $45.59
    Value
    $1.82M
  • Jergensen JoshuaSale

    15 Jul 2026, President & COO

    Shares
    40,000
    Price
    $45.02
    Value
    $1.8M
  • Hancock MarkSale

    15 Jul 2026, Board

    Shares
    3,332
    Price
    $45.05
    Value
    $150,115
  • Hancock MarkSale

    14 Jul 2026, Board

    Shares
    10,296
    Price
    $45.04
    Value
    $463,680
  • Hancock MarkSale

    9 Jul 2026, Board

    Shares
    4,966
    Price
    $45.06
    Value
    $223,781
  • Hancock MarkSale

    8 Jul 2026, Board

    Shares
    20,338
    Price
    $45.07
    Value
    $916,611
  • Lewis Michelle ReneeSale

    6 Jul 2026, Chief Accounting Officer

    Shares
    4,137
    Price
    $45.04
    Value
    $186,333
  • Hancock MarkSale

    6 Jul 2026, Board

    Shares
    142,163
    Price
    $45.33
    Value
    $6.44M
  • Lewis Michelle ReneeSale

    2 Jul 2026, Chief Accounting Officer

    Shares
    6,663
    Price
    $45.03
    Value
    $300,032
  • Hancock MarkSale

    2 Jul 2026, Board

    Shares
    12,825
    Price
    $45.01
    Value
    $577,290
  • Lewis Michelle ReneeSale

    1 Jul 2026, Chief Accounting Officer

    Shares
    4,200
    Price
    $45.01
    Value
    $189,059
  • Hancock MarkSale

    1 Jul 2026, Board

    Shares
    6,080
    Price
    $45.02
    Value
    $273,716
  • Hancock MarkSale

    26 Jun 2026, 10 percent owner, officer: Co Fndr; Exec V Chair

    Shares
    61,931
    Price
    $40.50
    Value
    $2.51M
  • Hancock MarkSale

    25 Jun 2026, 10 percent owner, officer: Co Fndr; Exec V Chair

    Shares
    138,069
    Price
    $40.33
    Value
    $5.57M
  • Lewis Michelle ReneeSale

    25 Jun 2026, Chief Accounting Officer

    Shares
    15,000
    Price
    $40.01
    Value
    $600,179
  • Hancock MarkSale

    17 Jun 2026, 10 percent owner, officer: Co Fndr; Exec V Chair

    Shares
    63,680
    Price
    $35.31
    Value
    $2.25M
  • Hancock MarkSale

    16 Jun 2026, 10 percent owner, officer: Co Fndr; Exec V Chair

    Shares
    83,066
    Price
    $35.90
    Value
    $2.98M
  • Hancock MarkSale

    15 Jun 2026, 10 percent owner, officer: Co Fndr; Exec V Chair

    Shares
    153,254
    Price
    $36.34
    Value
    $5.57M
  • Mitchell John ToddSale

    18 May 2026, Chief Legal Officer & Sec.

    Shares
    27,389
    Price
    $37.16
    Value
    $1.02M
  • Mitchell John ToddSale

    15 May 2026, Chief Legal Officer & Sec.

    Shares
    52,763
    Price
    $38.02
    Value
    $2.01M

Partial trades from one filing are shown in one row, with the average price.

Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.

What happened at PACS Group

The key events of the last six months from our own data. A click takes you to the matching card.

Sector comparison

714 rated companies in Healthcare

Rank 187 of 714
187/ 714
This company
67
Sector median
53

Categories against the sector median

ProfitabilityMedian of 714 companies50 (median 37)13 above the median
GrowthMedian of 714 companies88 (median 53)35 above the median
FundamentalsMedian of 714 companies79 (median 46)33 above the median
ValuationMedian of 477 companies with a value52 (median 54)2 below the median
StabilityMedian of 714 companies33 (median 67)34 below the median
Capital allocationMedian of 714 companies38 (median 39)1 below the median
Technical analysisMedian of 714 companies89 (median 70)19 above the median
MomentumMedian of 714 companies93 (median 71)22 above the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Medical (Care Facilities)

The next larger and next smaller companies by market value

All 56 Medical (Care Facilities) stocks

ETFs that hold PACS Group

Held by 15 ETFs on Xetra. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
iShares Ageing Population UCITS ETF2B770.21%0.40%€807M
L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ0.16%0.30%€185.82M
Avantis Global Small Cap Value UCITS ETFAVWS0.09%0.39%€1.47B
Show 5 more
State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR0.08%0.30%€4.22B
Xtrackers Russell 2000 UCITS ETF 1CXRS20.08%0.30%€2.17B
State Street SPDR Morningstar Multi-Asset Global Infrastructure UCITS ETF (Dist)ZPRI0.03%0.40%€622.34M
iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG0.03%0.43%€2.48B
State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS0.02%0.45%€1.53B

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data status and sources

Score
Daily value of 12 Nov 2026, recalculated nightly
Price
Closing price of 11 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Original filings at the SECReport a data error

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Neutral, published since 7 Nov 2026 (in the score history since 21 Nov 2025)
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
Full disclosures, methodology and data sourcesAll ratings of the last 12 monthsHow the score is calculated

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy